Device Post-Market Work In Scope Under MHRA’s 16% Cost Coverage Fee Hike
Bad News Or Balanced And Necessary? System Users To Have Their Say
Executive Summary
The UK MHRA has given medtech companies and stakeholders seven weeks to comment on proposed use fee rises for 2025. 16% rises are mooted for a variety of services.